Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
IL2
TNFa
adenovirus
head and neck cancer
immune checkpoint inhibitor
immunotherapy
oncolytic virotherapy
tertiary lymphoid neogenesis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
10
2021
accepted:
14
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) have provided significant improvement in clinical outcomes for some patients with solid tumors. However, for patients with head and neck cancer, the response rate to ICI monotherapy remains low, leading to the exploration of combinatorial treatment strategies. In this preclinical study, we use an oncolytic adenovirus (Ad5/3) encoding hTNFα and hIL-2 and non-replicate adenoviruses (Ad5) encoding mTNFα and mIL-2 with ICI to achieve superior tumor growth control and improved survival outcomes. The
Identifiants
pubmed: 35355980
doi: 10.3389/fimmu.2022.794251
pmc: PMC8959099
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Interleukin-2
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
794251Informations de copyright
Copyright © 2022 Clubb, Kudling, Heiniö, Basnet, Pakola, Cervera Carrascón, Santos, Quixabeira, Havunen, Sorsa, Zheng, Salo, Bäck, Aro, Tulokas, Loimu and Hemminki.
Déclaration de conflit d'intérêts
Authors JC, VCC, JMS, RH, SS, AH were employed by the company TILT Biotherapeutics Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from TILT Biotherapeutics Ltd. The funder had the following involvement in the study: permission to use oncolytic adenovirus TILT-123.
Références
Front Immunol. 2021 Jul 23;12:706517
pubmed: 34367166
Nat Commun. 2021 Jun 7;12(1):3349
pubmed: 34099645
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2480-9
pubmed: 23610399
Oral Oncol. 2018 Oct;85:35-39
pubmed: 30220317
J Immunother. 2016 Nov/Dec;39(9):343-354
pubmed: 27741089
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Immunol. 1998 Jan 1;160(1):485-91
pubmed: 9552007
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Cancer Immunol Res. 2015 Aug;3(8):915-25
pubmed: 25977260
Head Neck. 2000 Oct;22(7):680-6
pubmed: 11002323
Cancer. 1991 Jun 1;67(11):2741-7
pubmed: 2025837
Int Immunol. 2015 Oct;27(10):479-86
pubmed: 26071023
Front Immunol. 2020 Sep 18;11:1721
pubmed: 33072064
World J Gastroenterol. 2014 Jan 21;20(3):684-98
pubmed: 24574742
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Int Immunol. 1994 Dec;6(12):1883-90
pubmed: 7535097
Nat Commun. 2017 Nov 13;8(1):1443
pubmed: 29129929
Cell Rep. 2016 Nov 1;17(6):1571-1583
pubmed: 27806296
Oral Oncol. 2018 Apr;79:64-70
pubmed: 29598952
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
BMC Clin Pathol. 2014 Aug 23;14:38
pubmed: 25177210
Mol Ther. 2016 Aug;24(8):1435-43
pubmed: 27357626
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
J Exp Med. 2009 Nov 23;206(12):2593-601
pubmed: 19917776
Nature. 2021 Sep;597(7875):274-278
pubmed: 33208941
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900863
Oncotarget. 2017 Mar 17;8(33):55600-55612
pubmed: 28903447
Front Immunol. 2021 Mar 08;12:626776
pubmed: 33763071
Clin Cancer Res. 2017 Jan 1;23(1):250-262
pubmed: 27354470
Open Virol J. 2012;6:241-8
pubmed: 23341859
Immunity. 2012 Apr 20;36(4):586-99
pubmed: 22520852
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Gynecol Oncol. 2016 Jan;27(1):e2
pubmed: 26463431
J Infect Dis. 2007 May 1;195(9):1340-4
pubmed: 17397005
Cell Death Dis. 2020 Jan 22;11(1):48
pubmed: 31969562
Immunity. 2020 Jan 14;52(1):151-166.e6
pubmed: 31924474
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Oncoimmunology. 2018 Apr 9;7(5):e1412902
pubmed: 29721366
J Exp Med. 2008 Mar 17;205(3):543-55
pubmed: 18332181
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570278
PLoS One. 2015 Jun 24;10(6):e0131242
pubmed: 26107883
Cells. 2021 Jan 27;10(2):
pubmed: 33513935
Oncoimmunology. 2020 May 22;9(1):1761229
pubmed: 32923123
Ann Oncol. 2017 Jul 01;28(7):1605-1611
pubmed: 28419181
Mol Cancer Ther. 2018 Sep;17(9):2060-2071
pubmed: 29970484
Cells. 2020 Mar 26;9(4):
pubmed: 32225009
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):908-14
pubmed: 16702369
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Oncotarget. 2018 Jan 5;9(5):6320-6335
pubmed: 29464075
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7
pubmed: 21670304
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
pubmed: 17237035
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588